<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537966</url>
  </required_header>
  <id_info>
    <org_study_id>INFZ-ZPHI-01.01</org_study_id>
    <nct_id>NCT00537966</nct_id>
  </id_info>
  <brief_title>Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study</brief_title>
  <official_title>Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study: To describe the epidemiology, longitudinally follow, test the effect of
      early antiretroviral treatment and investigate early events of virus-host interactions in
      patients with documented acute or recent HIV-1 infection in Zurich.

      Study design: This is an open label, non-randomized, observational, single center study at
      the University Hospital Zurich, Division of Infectious Diseases and Hospital Epidemiology. We
      aim at enrolling approximately 300 patients over a 10 year period. All patients who fulfill
      the inclusion criteria of a documented acute or recent HIV infection can participate in the
      study. Patients are offered early combination antiretroviral treatment (cART), if treatment
      start falls within 90 days after diagnosis of acute HIV-infection. After one year of
      suppressed HIV-plasma viremia (&lt; 50 copies/ml) patients can chose to stop cART. Patients who
      have not chosen to undergo early-cART, respectively will stop cART after one year will be
      followed for a total of 5 years. Viral setpoints reached after treatment interruptions will
      be compared to historic controls and to the control group not having received cART during
      acute infection. A battery of virological and immunological assays will be performed on blood
      samples obtained to better understand early virus-host interactions, which are thought to
      play a key role in HIV-pathogenesis research.

      Summary: In summary, this study will provide comprehensive knowledge on early HIV-infection
      with regard to epidemiology, impact of early-cART on the course of disease and forms the base
      for a variety of translational research projects addressing early key pathogenesis events
      between virus and host, relevant for the course of disease, for transmission, for development
      of vaccines and new treatment strategies.

        -  Trial with medicinal product
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By the end of 2017 we have enrolled 450 patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of early-cART on the viral setpoint</measure>
    <time_frame>2016</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2017</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with primary HIV-1 infection who do not want to undergo early combination antiretroviral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm patients with primary HIV-1 infection will receive early combination antiretroviral therapy with standard drugs approved by Swiss Medic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>In this arm patients with primary HIV-1 infection are treated with standard antiretroviral combination therapy (only drugs that have been approved by Swiss Medic)</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Tivicay</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate</intervention_name>
    <description>standard dosage</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Genvoya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>standard dosage</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>standard dosage</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>used only as booster for the protease inhibitors that are prescribed in this study according to standard boosting</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilpivirine</intervention_name>
    <description>standard dosage</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Edurant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>standard dosage</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>3TC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir</intervention_name>
    <description>standard dosage</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>standard dosage</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Emtriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir</intervention_name>
    <description>standard dosage</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Ziagen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        A) Acute HIV-1 infection, defined as:

          -  Acute retroviral syndrome [78] (ARS) and negative or indeterminate Westernblot in the
             presence of a positive p24 Ag and/or detectable plasma HIV-1 RNA

          -  Documented seroconversion with or without symptoms within 90 days.

        or

        B) Recent HIV-1 infection, defined as:

          -  Possible ARS, positive Westernblot and detectable HIV-RNA, and a negative HIV-gp120
             avidity [82, 83], respectively detuned assay [84].

          -  Documented acute HIV-1 infection, however, referral to our center more than 90 days
             after presumed date of infection.

        Exclusion criteria:

          -  Hemoglobin &lt; 10 g/dl (men) and &lt; 9 g/dl (women) at the time of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huldrych. G端nthard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huldrych G端nthard, MD</last_name>
    <phone>+41 (0)44 255 11 11</phone>
    <email>Huldrych.Guenthard@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huldrych. G端nthard</last_name>
      <email>Huldrych.guenthard@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, G端nthard HF, Trkola A. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol. 2005 Jul;79(13):8454-69.</citation>
    <PMID>15956589</PMID>
  </reference>
  <reference>
    <citation>Joos B, Trkola A, Fischer M, Kuster H, Rusert P, Leemann C, B旦ni J, Oxenius A, Price DA, Phillips RE, Wong JK, Hirschel B, Weber R, G端nthard HF; Swiss HIV Cohort Study. Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J Virol. 2005 Jul;79(14):9026-37.</citation>
    <PMID>15994796</PMID>
  </reference>
  <reference>
    <citation>Aceto L, Karrer U, Grube Ch, Oberholzer R, Hasse B, Presterl E, B旦ni J, Kuster H, Trkola A, Weber R, G端nthard HF. [Primary HIV-1 infection in Zurich: 2002-2004]. Praxis (Bern 1994). 2005 Aug 10;94(32):1199-205. German.</citation>
    <PMID>16128207</PMID>
  </reference>
  <reference>
    <citation>Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, G端nthard HF. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother. 2006 May;50(5):1773-9.</citation>
    <PMID>16641449</PMID>
  </reference>
  <reference>
    <citation>Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Nieder旦st B, Weber R, von Wyl V, G端nthard HF, Trkola A. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med. 2006 Nov;3(11):e441.</citation>
    <PMID>17121450</PMID>
  </reference>
  <reference>
    <citation>Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Nieder旦st B, Weber R, Stiegler G, Katinger H, G端nthard HF, Trkola A. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol. 2007 Aug;81(16):8793-808. Epub 2007 Jun 13.</citation>
    <PMID>17567707</PMID>
  </reference>
  <reference>
    <citation>Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, Stiegler G, Katinger H, Joos B, G端nthard HF. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol. 2008 Feb;82(3):1591-9. Epub 2007 Nov 21.</citation>
    <PMID>18032508</PMID>
  </reference>
  <reference>
    <citation>Huber M, von Wyl V, Ammann CG, Kuster H, Stiegler G, Katinger H, Weber R, Fischer M, Stoiber H, G端nthard HF, Trkola A. Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J Virol. 2008 Apr;82(8):3834-42. doi: 10.1128/JVI.02569-07. Epub 2008 Jan 30.</citation>
    <PMID>18234794</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary HIV Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

